Humana Inc

Humana Inc(HUM)股票分析

$425.420

-1.957 (-0.46%)收盤時

Loading chart…
最高
434.125
開盤
431.520
成交量加權均價
427.80
成交量
1.48M
市值
43.74B
最低
423.850
成交金額
632.27M
企業價值/稅息折舊攤銷前利潤(TTM)
8.64

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.

AI 分析 of Humana Inc (HUM)

買進

Humana Inc is a good buy right now due to its recent performance and strong fundamentals. The stock is currently priced at $413.16, which is below the analyst price target range of $475 to $525, indicating potential upside. Additionally, the company has improved its Medicare Advantage ratings significantly, with 95% of its members now in plans rated four stars or higher, which could lead to an estimated $3.6 billion in additional revenue. However, the main risk is the recent decline in stock price, with a 5-day change of -4.33%.

分析師評級(19)

-31.74% 下跌空間
買進
12 買進
7 持有
0 賣出
目前: 425.42
最低
231.00
平均
290.39
最高
344.00

UBS

2026-10-12

目標價

$495

中性

Oppenheimer

2026-10-12

目標價

$525

優於大盤

Truist

2026-10-12

目標價

$475

持有

Raymond James

2026-10-12

目標價

$520

優於大盤

Oppenheimer

2026-10-09

目標價

$475

優於大盤

估值指標

Humana Inc(HUM)目前預期本益比為 24.33,5 年平均預期本益比為 20.23。

預期本益比

合理
5 年均值 P/E
20.23
目前P/E
24.33
高估
26.14
低估
14.31

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
10.62
目前EV/EBITDA
8.64
高估
14.52
低估
6.71

預期股價營收比

合理
5 年均值 P/S
0.42
目前P/S
0.30
高估
0.59
低估
0.24

Alphio AI 對 HUM 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%HUM

$253.64

情境價格

基

基準

基準 · 50%HUM

$209.60

情境價格

悲

悲觀

悲觀 · 25%HUM

$179.91

情境價格

持有 HUM 的大戶

B

Braidwell LP

+ 持有HUMTMO

+24.27%

3個月報酬率

V

Vulcan Value Partners, LLC

+ 持有HUM

+9.59%

3個月報酬率

H

Hotchkis and Wiley Capital Management, LLC

+ 持有HUM

+8.75%

3個月報酬率

P

PDT Partners, LLC

+ 持有HUM

+8.23%

3個月報酬率

S

South Dakota Investment Council

+ 持有HUM

+7.44%

3個月報酬率

B

Barrow, Hanley, Mewhinney & Strauss, LLC

+ 持有HUM

+6.55%

3個月報酬率

事件時間軸

2026-10-13 (ET)

06:30:00

Humana Forms New Joint Venture with BlackRock

2026-10-09 (ET)

16:30:00

Trump Says U.S. Will Not Strike Iran, Oil Pulls Back

12:30:00

Humana Stock Rises 12.8% to $436.60

12:00:00

Tech Stock Rebound Boosts Major Averages

10:30:00

Humana Stock Rises 14.7% to $443.99

資訊

HUM 常見問題 —— 由 Alphio AI 解答

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Humana Inc is a good buy right now due to its recent performance and strong fundamentals. The stock is currently priced at $413.16, which is below the analyst price target range of $475 to $525, indicating potential upside. Additionally, the company has improved its Medicare Advantage ratings significantly, with 95% of its members now in plans rated four stars or higher, which could lead to an estimated $3.6 billion in additional revenue. However, the main risk is the recent decline in stock price, with a 5-day change of -4.33%.

19 analysts cover HUM: 12 rate it Buy, 7 Hold and 0 Sell. The average price target is 290.39.

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易